NuCana plc ADR
NCNA
NuCana plc ADR is a clinical-stage biopharmaceutical company focused on developing cancer medicines using its proprietary ProTide technology. The company’s current work centers on transforming established chemotherapy agents and nucleoside analogs into new therapies designed for oncology use. Its pipeline includes investigational programs aimed at addressing solid tumors and improving how anti-cancer compounds are delivered inside cancer cells. NuCana plc ADR represents the company’s U.S.-traded depositary shares, providing market access to an oncology-focused biotechnology business based in Edinburgh, United Kingdom. In the financial markets, the asset is followed for its drug development pipeline, clinical progress, and broader positioning within the biotechnology sector.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£10M
▼ -54.5% YoY
Op. Margin
–
ROIC
-105.68%
▲ +34.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£5M
▲ +60.5% YoY
Op. Cash Flow (TTM)
-£5M
▲ +61.5% YoY
Net Debt
-£24M
Net Cash Position
Cash & Equiv.
£24M
Continue Research
Peers
Biotechnology · Pick stocks to compare with NCNA
NuCana plc ADR (NCNA) in two numbers
Questions about NuCana plc ADR
Is NuCana plc ADR a high-quality business?
NuCana plc ADR scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$24M, and its weakest is return on capital at -105.7%. The Quality tab shows every check against its target.
Does NuCana plc ADR (NCNA) pay a dividend?
No. NuCana plc ADR (NCNA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NCNA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.